ROCKWELL MEDICAL, INC. (NASDAQ:RMTI) Files An 8-K Regulation FD Disclosure

On June 29, 2020, Rockwell Medical, Inc. made available an updated corporate presentation. A copy of the corporate presentation is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

(d) Exhibits. The following exhibit is being filed herewith:

EXHIBIT INDEX

ROCKWELL MEDICAL, INC. Exhibit
EX-99.1 2 rockwellmedinvestorprese.htm EXHIBIT 99.1 rockwellmedinvestorprese JUNE/JULY 2020   Forward Looking Language Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws,…
To view the full exhibit click here

About ROCKWELL MEDICAL, INC. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.